Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Income from Continuing Operations (2022 - 2026)

Indivior Pharmaceuticals has reported Income from Continuing Operations over the past 5 years, most recently at 89000000.0 for Q1 2026.

  • For Q1 2026, Income from Continuing Operations rose 85.42% year-over-year to 89000000.0; the TTM value through Mar 2026 reached 251000000.0, up 3685.71%, while the annual FY2025 figure was 210000000.0, 2900.0% up from the prior year.
  • Income from Continuing Operations for Q1 2026 was 89000000.0 at Indivior Pharmaceuticals, down from 102000000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 102000000.0 in Q4 2025 and troughed at 329000000.0 in Q4 2022.
  • A 5-year average of 6875000.0 and a median of 55000000.0 in 2024 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 438.81% in 2023 and later surged 385.71% in 2025.
  • Year by year, Income from Continuing Operations stood at 329000000.0 in 2022, then skyrocketed by 120.67% to 68000000.0 in 2023, then tumbled by 69.12% to 21000000.0 in 2024, then surged by 385.71% to 102000000.0 in 2025, then decreased by 12.75% to 89000000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for INDV at 89000000.0 in Q1 2026, 102000000.0 in Q4 2025, and 42000000.0 in Q3 2025.